Interna TX
Petah Tikva, Israel· Est.
A platform biotech that uses a Molecular Nano Motor to deliver macromolecule drugs intracellularly for respiratory indications.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $10.3M
AI Company Overview
A platform biotech that uses a Molecular Nano Motor to deliver macromolecule drugs intracellularly for respiratory indications.
Infectious diseasesPulmonary diseases
Technology Platform
Molecular Nano Motor (MNM) – a chemically conjugated moiety that uses cell‑membrane electrical forces to deliver macromolecules intracellularly and then releases the cargo in the cytoplasm.
Opportunities
The MNM platform can be licensed to pharma companies for a broad range of macromolecule therapeutics, and its intranasal route opens a large market in respiratory prophylaxis and treatment.
Risk Factors
Technology has limited human data beyond Phase I, and regulatory approval may be challenging; competition from established delivery systems could limit adoption.
Competitive Landscape
Competitors include lipid nanoparticle and cell‑penetrating peptide platforms; Interna differentiates through a membrane‑electric‑force mechanism that offers universal cargo attachment and potentially lower systemic exposure.